IDEXX Laboratories, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Erickson
- Full Time Employees
- 11,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- One IDEXX Drive Westbrook ME United States of America 04092
- IPO Date
- Jun 21, 1991
- CIK
- 0000874716
- Website
- idexx.com
- Similar Companies
- Business
- IDEXX Laboratories, Inc. (IDXX) develops, manufactures, and distributes diagnostic products, equipment, and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing industries. The company offers an extensive portfolio of in-clinic analyzers including the Catalyst One Chemistry Analyzer, ProCyte Dx Hematology Analyzer, SediVue Dx Urine Sediment Analyzer, and SNAP point-of-care tests; reference laboratory services for advanced diagnostics; veterinary software solutions such as IDEXX Neo and Cornerstone practice management software, VetLab Station laboratory information management system, and client communication tools; diagnostic imaging systems like ImageVue DR50 and EliteVision; and specialized tests for ruminants (e.g., BVDV, IBR/BHV-1, Johne's Disease), poultry (e.g., IBV, IBD), swine (e.g., PRRS, PEDV), equine health (e.g., EHV-1/4 RealPCR, EPM tests), and water quality microbiological detection serving over 2.5 billion people. IDEXX also provides OPTI Medical Systems for human point-of-care and laboratory diagnostics. Founded in 1983 and headquartered in Westbrook, Maine, the company operates in over 175 countries through its three main segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy (LPD), with additional EMEA headquarters in Hoofddorp, Netherlands, and approximately 10,000 employees worldwide. Recent developments include the strong adoption of the inVue Dx Cellular Analyzer with over 2,400 units installed in Q2 2025, surpassing expectations and prompting a full-year installation forecast increase to 5,500 units; the June 2025 launch of the Catalyst Cortisol Test, the third Catalyst platform expansion that year, enhancing point-of-care diagnostics for endocrine disorders like Addison's and Cushing's disease in dogs; the North American rollout of IDEXX Cancer Dx; upward revisions to 2025 revenue guidance to $4.27 billion-$4.30 billion and EPS to $12.81-$13.01 amid 11% Q2 revenue growth and 13% Q3 growth driven by recurring CAG diagnostics; and sustained R&D investment at about 5.75% of revenue to support platform expansions, AI-driven solutions, molecular tests, international commercial footprint growth in three countries by 2026, and software enhancements.
Company News
Should You Continue to Hold IDXX Stock in Your Portfolio?
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
IDEXX Stock Gains Following the Acquisition of CoVet
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Financial Analysis: IDEXX Laboratories (NASDAQ:IDXX) vs. InMode (NASDAQ:INMD)
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock
Baird Financial Group Inc. Sells 6,500 Shares of IDEXX Laboratories, Inc. $IDXX
Arizona State Retirement System Purchases 1,074 Shares of IDEXX Laboratories, Inc. $IDXX
IDEXX Laboratories, Inc. $IDXX Stake Boosted by California State Teachers Retirement System
Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Baron Focused Growth Fund Q2 2026 Portfolio Update
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?